$5,799.00
In Stock
Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, the treatment of patients with atypical hemolytic uremic syndrome to suppress complement-mediated thrombotic microangiopathy, the treatment of adult patients with generalized myasthenia gravis who are positive for the antibody against acetylcholine receptor and optical spectrum disorder neuromyelitis in adult patients.
The drug has received several awards for innovation in the pharmaceutical industry, including the 2008 Prix Galien USA Award for Best Biotechnology Product and the 2009 Prix Galien France Award for Orphan Drugs.
Active ingredient: eculizumab
Storage temperature 2-8 degrees
Prescription medicine
